Top

Published in:

Open Access 01-12-2022 | Thrombotic Microangiopathy | Research

Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis

Authors: Jingnan Feng, Ke Xu, Xinmiao Shi, Lu Xu, Lili Liu, Fang Wang, Xuhui Zhong, Guozhen Liu, Jinxi Wang, Pei Gao, Jie Ding, Shengfeng Wang, Siyan Zhan

Published in: BMC Nephrology | Issue 1/2022

Abstract

Background

Haemolytic uraemic syndrome (HUS) is a severe syndrome that causes a substantial burden for patients and their families and is the leading cause of acute kidney injury in children. However, data on the epidemiology and disease burden of HUS in Asia, including China, are limited. We aimed to estimate the incidence and cost of HUS in China.

Methods

Data about HUS from 2012 to 2016 were extracted from the Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI) databases. All cases were identified by ICD code and Chinese diagnostic terms. The 2016 national incidence rates were estimated and stratified by sex, age and season. The associated medical costs were also calculated.

Results

The crude incidence of HUS was 0.66 per 100,000 person-years (95% CI: 0.35 to 1.06), and the standardized incidence was 0.57 (0.19 to 1.18). The incidence of HUS in males was slightly higher than that in females. The age group with the highest incidence of HUS was patients < 1 year old (5.08, 95% CI: 0.23 to 24.87), and the season with the highest incidence was autumn, followed by winter. The average cost of HUS was 2.15 thousand US dollars per patient, which was higher than the national average cost for all inpatients in the same period.

Conclusions

This is the first population-based study on the incidence of HUS in urban China. The age and seasonal distributions of HUS in urban China are different from those in most developed countries, suggesting a difference in aetiology.

Available only for authorised users

Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, et al. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15–39. https://doi.org/10.1007/s00467-015-3076-8.CrossRefPubMed

Tarr PI, Gordon CA, Chandler WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005;365(9464):1073–86. https://doi.org/10.1016/s0140-6736(05)71144-2.CrossRefPubMed

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539–51. https://doi.org/10.1016/j.kint.2016.10.005.CrossRefPubMed

Lemaire M, Noone D, Lapeyraque AL, Licht C, Frémeaux-Bacchi V. Inherited kidney complement diseases. Clin J Am Soc Nephrol. 2021;16(6):942–56. https://doi.org/10.2215/cjn.11830720.CrossRefPubMed

Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(4):1035–50. https://doi.org/10.1681/asn.2004100861.CrossRefPubMed

Caletti MG, Petetta D, Jaitt M, Casaliba S, Gimenez A. Hemolytic uremic syndrome (HUS): medical and social costs of treatment. Medicina. 2006;66(Suppl 3):22–6.PubMed

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169–81. https://doi.org/10.1056/NEJMoa1208981.CrossRefPubMed

Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 2001;60(3):831–46. https://doi.org/10.1046/j.1523-1755.2001.060003831.x.CrossRefPubMed

Vally H, Hall G, Dyda A, Raupach J, Knope K, Combs B, et al. Epidemiology of shiga toxin producing escherichia coli in Australia, 2000–2010. BMC Public Health. 2012;12:63. https://doi.org/10.1186/1471-2458-12-63.CrossRefPubMedPubMedCentral

10.

Yan K, Desai K, Gullapalli L, Druyts E, Balijepalli C. Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review. Clin Epidemiol. 2020;12:295–305. https://doi.org/10.2147/CLEP.S245642.CrossRefPubMedPubMedCentral

11.

Shi XM, Liu H, Wang L, Wang ZX, Dong CY, Wang YF, et al. Study on the current situation of China’s first list of rare diseases based on 15 million hospitalizations. Zhonghua Yi Xue Za Zhi. 2018;98(40):3274–8. https://doi.org/10.3760/cma.j.issn.0376-2491.2018.40.012.CrossRefPubMed

12.

Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, et al. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis. 2012;54(10):1413–21. https://doi.org/10.1093/cid/cis196.CrossRefPubMed

13.

Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67(11):974–8. https://doi.org/10.1136/jech-2013-203104.CrossRefPubMed

14.

Torti JF, Cuervo P, Nardello A, Pizarro M. Epidemiology and characterization of shiga toxin-producing escherichia coli of hemolytic uremic syndrome in Argentina. Cureus. 2021;13(8): e17213. https://doi.org/10.7759/cureus.17213.CrossRefPubMedPubMedCentral

15.

Haack JP, Jelacic S, Besser TE, Weinberger E, Kirk DJ, McKee GL, et al. Escherichia coli o157 exposure in wyoming and seattle: serologic evidence of rural risk. Emerg Infect Dis. 2003;9(10):1226–31. https://doi.org/10.3201/eid0910.020254.CrossRefPubMed

16.

Crump JA, Sulka AC, Langer AJ, Schaben C, Crielly AS, Gage R, et al. An outbreak of Escherichia coli O157:H7 infections among visitors to a dairy farm. N Engl J Med. 2002;347(8):555–60. https://doi.org/10.1056/NEJMoa020524.CrossRefPubMed

17.

Karimi M, Sabzi A, Peyvandi F, Mannucci PM. Changing epidemiology of the hemolytic uremic syndrome and thrombotic thrombocytopenic purpura in southern Iran. Journal of thrombosis and haemostasis : JTH. 2006;4(3):701–2. https://doi.org/10.1111/j.1538-7836.2006.01807.x.CrossRefPubMed

18.

Marder Mph EP, Griffin PM, Cieslak PR, Dunn J, Hurd S, Jervis R, et al. Preliminary incidence and trends of infections with pathogens transmitted commonly through food - foodborne diseases active surveillance network, 10 U.S. Sites, 2006-2017. MMWR Morb Mortal Wkly Rep. 2018;67(11):324–8.CrossRef

19.

Quinlan JJ. Foodborne illness incidence rates and food safety risks for populations of low socioeconomic status and minority race/ethnicity: a review of the literature. Int J Environ Res Public Health. 2013;10(8):3634–52. https://doi.org/10.3390/ijerph10083634.CrossRefPubMedPubMedCentral

20.

Whitney BM, Mainero C, Humes E, Hurd S, Niccolai L, Hadler JL. Socioeconomic status and foodborne pathogens in connecticut, USA, 2000–2011(1). Emerg Infect Dis. 2015;21(9):1617–24. https://doi.org/10.3201/eid2109.150277.CrossRefPubMedPubMedCentral

21.

Sheth KJ, Gill JC, Havens PL, Leichter HE. Racial incidence of hemolytic-uremic syndrome. Pediatr Nephrol. 1995;9(3):401. https://doi.org/10.1007/bf02254233.CrossRefPubMed

22.

Wang CY, Shen Q, Sun L, Li GM, Wu BB, Xu H. Analysis of genotype-phenotype correlation in 14 patients with atypical hemolytic uremic syndrome. Chinese Journal of Evidence-Based Pediatrics. 2017;12(1):54–9.

23.

Lee JM, Park YS, Lee JH, Park SJ, Shin JI, Park YH, et al. Atypical hemolytic uremic syndrome: Korean pediatric series. Pediatr Int. 2015;57(3):431–8. https://doi.org/10.1111/ped.12549.CrossRefPubMed

24.

Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011;365(19):1771–80. https://doi.org/10.1056/NEJMoa1106483.CrossRefPubMed

25.

Miller DP, Kaye JA, Shea K, Ziyadeh N, Cali C, Black C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004;15(2):208–15. https://doi.org/10.1097/01.ede.0000113273.14807.53.CrossRefPubMed

26.

Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, et al. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. Eur J Pediatr. 2016;175(4):465–73. https://doi.org/10.1007/s00431-015-2642-1.CrossRefPubMed

27.

Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, et al. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392–400. https://doi.org/10.1681/asn.2006080811.CrossRefPubMed

28.

Pediatric Blood Purification Specialist Commite of Pediatric Association in Chinese Medical Doctor Association. A multi-center epidemiological investigation on therapeutic plasma exchange for the children with hemolytic uremic syndrome. Chin J Appl Clin Pediatr. 2018;33(13):1022–7.

29.

Li J, Song Y, Zhang Y, Li H, Tian M, Li D, et al. A novel compound heterozygous mutation in DGKE in a Chinese patient causes atypical hemolytic uremic syndrome. Hematol (Amsterdam, Netherlands). 2020;25(1):101–7. https://doi.org/10.1080/16078454.2020.1731969.CrossRef

30.

So CC, Leung YY, Yip SF, Chan SY, Lam CC, Chan GC, et al. Common association of haemolytic uraemic syndrome with invasive Streptococcus pneumoniae infection in five Chinese paediatric patients. Hong Kong Med J = Xianggang yi xue za zhi. 2011;17(3):237–41.PubMed

31.

Lee CS, Chen MJ, Chiou YH, Shen CF, Wu CY, Chiou YY. Invasive pneumococcal pneumonia is the major cause of paediatric haemolytic-uraemic syndrome in Taiwan. Nephrol (Carlton). 2012;17(1):48–52. https://doi.org/10.1111/j.1440-1797.2011.01500.x.CrossRef

Title: Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis
Authors: Jingnan Feng
Ke Xu
Xinmiao Shi
Lu Xu
Lili Liu
Fang Wang
Xuhui Zhong
Guozhen Liu
Jinxi Wang
Pei Gao
Jie Ding
Shengfeng Wang
Siyan Zhan
Publication date: 01-12-2022
Publisher: BioMed Central
Keyword: Thrombotic Microangiopathy
Published in: BMC Nephrology / Issue 1/2022
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-022-02746-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Incidence and cost of haemolytic uraemic syndrome in urban China: a national population-based analysis

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis

A study protocol for improving the delivery of acute kidney replacement therapy (KRT) to critically ill patients in Alberta – DIALYZING WISELY

The association of urinary prostaglandins with uric acid in hyperuricemia patients

Artificial intelligence for the prediction of acute kidney injury during the perioperative period: systematic review and Meta-analysis of diagnostic test accuracy

Impact of telehealth interventions added to peritoneal dialysis-care: a systematic review

Thrombotic thrombocytopenic purpura developed after pegylated interferon treatment for hepatitis B infection

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page